Q3 EPS Estimates for Bio-Techne Decreased by Leerink Partnrs

Bio-Techne Co. (NASDAQ:TECH) – Stock analysts at Leerink Partnrs decreased their Q3 2025 EPS estimates for shares of Bio-Techne in a research report issued to clients and investors on Thursday, April 17th. Leerink Partnrs analyst P. Souda now expects that the biotechnology company will post earnings per share of $0.45 for the quarter, down from their previous forecast of $0.47. The consensus estimate for Bio-Techne’s current full-year earnings is $1.67 per share. Leerink Partnrs also issued estimates for Bio-Techne’s Q4 2025 earnings at $0.50 EPS and FY2026 earnings at $2.06 EPS.

A number of other equities analysts have also commented on TECH. Evercore ISI initiated coverage on shares of Bio-Techne in a report on Tuesday, March 18th. They issued an “outperform” rating and a $75.00 price target on the stock. Royal Bank of Canada increased their target price on Bio-Techne from $79.00 to $80.00 and gave the company a “sector perform” rating in a research note on Thursday, February 6th. StockNews.com raised Bio-Techne from a “hold” rating to a “buy” rating in a research note on Thursday. KeyCorp reiterated a “sector weight” rating on shares of Bio-Techne in a research report on Wednesday, April 9th. Finally, Baird R W downgraded Bio-Techne from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 19th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Bio-Techne presently has an average rating of “Hold” and a consensus price target of $81.14.

Bio-Techne Stock Down 3.7 %

TECH stock opened at $48.10 on Friday. The company’s 50 day moving average is $59.09 and its 200 day moving average is $68.60. The stock has a market cap of $7.60 billion, a price-to-earnings ratio of 48.59, a price-to-earnings-growth ratio of 2.88 and a beta of 1.45. The company has a current ratio of 3.94, a quick ratio of 2.77 and a debt-to-equity ratio of 0.14. Bio-Techne has a 1-year low of $46.44 and a 1-year high of $85.57.

Bio-Techne (NASDAQ:TECH) last posted its earnings results on Wednesday, February 5th. The biotechnology company reported $0.35 EPS for the quarter, missing the consensus estimate of $0.38 by ($0.03). Bio-Techne had a return on equity of 12.73% and a net margin of 13.22%.

Institutional Trading of Bio-Techne

Hedge funds have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Bio-Techne by 46.6% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 16,650 shares of the biotechnology company’s stock worth $1,215,000 after buying an additional 5,295 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in Bio-Techne by 58.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 43,298 shares of the biotechnology company’s stock worth $3,119,000 after acquiring an additional 16,038 shares during the last quarter. Oddo BHF Asset Management Sas bought a new position in Bio-Techne in the 3rd quarter valued at approximately $1,188,000. Fort Washington Investment Advisors Inc. OH boosted its stake in Bio-Techne by 11.2% during the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 254,034 shares of the biotechnology company’s stock valued at $18,298,000 after purchasing an additional 25,650 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new stake in shares of Bio-Techne in the 4th quarter worth $3,940,000. 98.95% of the stock is owned by institutional investors.

Insider Buying and Selling at Bio-Techne

In related news, Director Amy E. Herr sold 1,860 shares of the firm’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $65.96, for a total value of $122,685.60. Following the completion of the sale, the director now owns 1,976 shares of the company’s stock, valued at $130,336.96. This trade represents a 48.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Kim Kelderman sold 13,392 shares of the firm’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $77.29, for a total transaction of $1,035,067.68. Following the completion of the sale, the chief executive officer now directly owns 39,004 shares of the company’s stock, valued at approximately $3,014,619.16. This represents a 25.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.90% of the stock is currently owned by corporate insiders.

Bio-Techne Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, February 28th. Investors of record on Monday, February 17th were issued a dividend of $0.08 per share. The ex-dividend date was Friday, February 14th. This represents a $0.32 dividend on an annualized basis and a yield of 0.67%. Bio-Techne’s dividend payout ratio is currently 32.32%.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.